Evidence map›Paper›PMID 38097915›Full record

ReviewMolecular neurobiology2024

Potential Plausible Role of Stem Cell for Treating Depressive Disorder: a Retrospective Review.

Zhuo Chang, Qing-Yi Wang, Lu-Hao Li, Bei Jiang, Xue-Ming Zhou, Hui Zhu, Yan-Ping Sun, Xue Pan, Xu-Xu Tu, Wei Wang and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Zhuo ChangHeilongjiang University of Chinese Medicine, Heping Road 26, Harbin, Heilongjiang, 150040, China.
Qing-Yi WangHeilongjiang University of Chinese Medicine, Heping Road 26, Harbin, Heilongjiang, 150040, China.
Lu-Hao LiHeilongjiang University of Chinese Medicine, Heping Road 26, Harbin, Heilongjiang, 150040, China.
Bei JiangHeilongjiang University of Chinese Medicine, Heping Road 26, Harbin, Heilongjiang, 150040, China.
Xue-Ming ZhouHeilongjiang University of Chinese Medicine, Heping Road 26, Harbin, Heilongjiang, 150040, China.
Hui ZhuHeilongjiang University of Chinese Medicine, Heping Road 26, Harbin, Heilongjiang, 150040, China.
Yan-Ping SunHeilongjiang University of Chinese Medicine, Heping Road 26, Harbin, Heilongjiang, 150040, China.
Xue PanThird Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, China.
Xu-Xu TuHeilongjiang University of Chinese Medicine, Heping Road 26, Harbin, Heilongjiang, 150040, China.
Wei WangFirst Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Chen-Yue LiuInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Hai-Xue KuangHeilongjiang University of Chinese Medicine, Heping Road 26, Harbin, Heilongjiang, 150040, China. hxkuang56@163.com.ORCID http://orcid.org/0000-0001-9136-8414
Heilongjiang University of Chinese Medicine · CNBeijing University of Chinese Medicine · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Heilongjiang University of Chinese Medicine · CN

Funding

Heilongjiang Touyan Innovation Team Program [2019] No. 5National Famous Old Traditional Chinese Medicine Experts Inheritance Studio Construction Program of National Administration of TCM [2022] No. 75National Traditional Chinese Medicine Inheritance and Innovation Talent Project [2021] No. 7Postdoctoral Research Start-up Project in Heilongjiang Province LBH-Q21193the Research Project of Heilongjiang Traditional Chinese Medicine Administration ZHY2022-110the Scientific research foundation of Heilongjiang University of traditional Chinese Medicine 2019MS34The Seventh Batch of National Famous Old Traditional Chinese Medicine Experts Experience Heritage Construction Program of National Administration of TCM [2022] No. 76
6 · The paper itself

Abstract

Depression poses a significant threat to global physical and mental health, impacting around 3.8% of the population with a rising incidence. Current treatment options primarily involve medication and psychological support, yet their effectiveness remains limited, contributing to high relapse rates. There is an urgent need for innovative and more efficacious treatment modalities. Stem cell therapy, a promising avenue in regenerative medicine for a spectrum of neurodegenerative conditions, has recently garnered attention for its potential application in depression. While much of this work remains preclinical, it has demonstrated considerable promise. Identified mechanisms underlying the antidepressant effects of stem cell therapy encompass the stimulation of neurotrophic factors, immune function modulation, and augmented monoamine levels. Nonetheless, these pathways and other undiscovered mechanisms necessitate further investigation. Depression fundamentally manifests as a neurodegenerative disorder. Given stem cell therapy's success in addressing a range of neurodegenerative pathologies, it opens the door to explore its application in depression treatment. This exploration may include repairing damaged nerves directly or indirectly and inhibiting neurotoxicity. Nevertheless, significant challenges must be overcome before stem cell therapies can be applied clinically. Successful resolution of these issues will ultimately determine the feasibility of incorporating stem cell therapies into the clinical landscape. This narrative review provides insights into the progress of research, potential avenues for exploration, and the prevailing challenges in the implementation of stem cell therapy for treatment of depression.

Indexed as

Depressive DisorderStem Cell TransplantationAnimalsHumansStem CellsDepressive disorderNeurodegenerative diseaseReviewStem cellsTherapy

Identifiers

PMID38097915
OpenAlexW4389721482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.